WO2014104671A1 - 테모졸로미드를 포함하는 안정성이 개선된 약제학적 조성물 및 이의 제조방법 - Google Patents
테모졸로미드를 포함하는 안정성이 개선된 약제학적 조성물 및 이의 제조방법 Download PDFInfo
- Publication number
- WO2014104671A1 WO2014104671A1 PCT/KR2013/011973 KR2013011973W WO2014104671A1 WO 2014104671 A1 WO2014104671 A1 WO 2014104671A1 KR 2013011973 W KR2013011973 W KR 2013011973W WO 2014104671 A1 WO2014104671 A1 WO 2014104671A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pharmaceutical composition
- temozolomide
- granules
- pharmaceutically acceptable
- dry
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Definitions
- the present invention relates to a granule comprising temozolomide, a pharmaceutical composition having improved stability comprising the same, and a preparation method thereof.
- Temozolomide is an anticancer drug that is a chemotherapeutic drug approved for the treatment of brain tumors (commercially available from Schering Corp. under the trade names Temodar® in the United States and Tetnodal® in Europe). .
- the chemical name of temozolomide is 3,4-dihydro-3-methyl-4-oxoimidazo [5,1—d] -as-tetrazin-8—carboxamide (see US Patent No. 5,260, 291), and its cytotoxicity is thought to be due to DNA alkylation of temozolomide and its metabolite MTIC (3-methyl- (triazin-1-yl) imidazole-4-carboxamide).
- Temozolomide is currently used in the US for the treatment of newly diagnosed glioblastoma multiforme and aplastic aplastic astrocytoma, and in Europe not only for newly diagnosed patients but also for relapse or progression after standard therapy. It is approved for the treatment of patients with malignant glioma, such as glioblastoma multiforme or anaplastic astrocytoma.
- Temozolomide on the other hand, has water-insoluble properties, and decomposes in wet conditions, high pH, above room temperature, and light. As a result, "temozolomide is white to pale pinkish or pale orange powder". It is known that the appearance turns into a "dark powder or orange powder”. Therefore, in order to stably formulate this drug, it is essential to improve the stability to the above conditions.
- temozolomide is available on the market in various dosages of 5, 20, 100, and 250 mg, and the content of the main ingredient is high per voxel, but the bulk of the drug is bulky and the flow is bad. There is a disadvantage that it is difficult to ensure the layering and content uniformity of the composition.
- the present invention has been made in order to solve the above problems, while maintaining the conventional dissolution pattern while suppressing the generation of the flexible material temozolomide-containing granules having a markedly improved water stability and storage stability, a pharmaceutical comprising the same It is an object to provide a pharmaceutical composition and a method for preparing the same.
- a pH stabilizer is mixed with temozolomide to prepare a granular form, which can significantly improve the stability of the pH and moisture, the packing property and the uniformity of the content.
- the present invention was completed by confirming that the above effects could be maximized.
- the formulation and content of the pharmaceutically acceptable additives added to the dry granules and the optimum conditions of the addition time were derived to provide a formulation having excellent physical properties.
- dry granules comprising temozolomide and tartaric acid as pH stabilizers are provided.
- another preferred embodiment of the present invention provides a pharmaceutical composition with improved stability comprising the granules and pharmaceutically acceptable additives.
- another preferred embodiment of the present invention comprises the steps of: a) mixing tartaric acid and tartaric acid as a pH stabilizer; b) forming and granulating dry granules with the mixture; And c) mixing the granulated granules with pharmaceutically acceptable additives.
- Granules according to a preferred embodiment of the present invention is characterized in that the dry granules containing the tarmoacid as the temozolomide and pH stabilizer.
- the pH stabilizer is included to adjust the pH of the granules and the pharmaceutical composition comprising the granules, and preferably tartaric acid may be used as the pH stabilizer, and the pH stabilizer may be used to adjust the pH of the pharmaceutical composition. Up to 5, for example pH 2-5.
- the pH stabilizer may be included in 1 to 50 parts by weight, more preferably 3 to 30 parts by weight based on 100 parts by weight of temozolomide.
- the granules may preferably further comprise an anti-caking agent.
- the anti-caking agent is used to prevent the binding of the hygroscopic component, but is not limited thereto.
- at least one selected from the group consisting of D-mannitol, colloidal silicon dioxide, calcium silicate, magnesium silicate, and calcium stearate is used. More preferably with distinctive small particles and a large surface area Due to this, it is possible to use colloidal silicon dioxide which can improve the flowability of the powder and the compression moldability.
- the anti-caking agent may be included in an amount of 0.05 to 0.1 parts by weight based on 100 parts by weight of temozolomide. If the anti-caking agent is used excessively in excess of the above range, the lubricant may be improved, but it may affect the dissolution or physical properties of the drug, so that the anti-caking agent is preferably in the above range in order to achieve the purpose of anti-caking while using a minimum amount. It is good to use
- the granules may further improve the preparation, flowability, and physical properties of the granules by additionally including one or more pharmaceutically acceptable additives.
- additives or excipients are collectively referred to as additives or excipients, and may preferably further include any one or more of excipients, binders, disintegrants, glidants, and diluents in the granules. have.
- Excipients may be included to ensure uniform volume and desired tableting, and uniformity of content, depending on the dose of temozolomide, the main agent.
- excipients include lactose, manny, starch, powdered white sugar, calcium phosphate, microcrystalline cellulose, colloidal silicon dioxide, and the like, as well as cost and suitability for the active ingredient.
- Other additives may also serve as excipients, in addition to their main use.
- the binder acts to improve the adhesion between the granules and to maintain the shape of the formulation after being compressed.
- examples include maltose, natural gum (Arabian gum), salose derivatives (methylcellulose, carboxymethylcellulose, microcrystalline cellulose), gelatin, povidone, and the like.
- Disintegrants may be added to promote disintegration or disintegration of the final formulation, and specifically serve to disintegrate upon contact with moisture to disrupt the tablet in the gastrointestinal tract.
- disintegrants for example, starch derivatives (corn starch, potato starch, sodium starch glycolate, croscarmellose), cellulose derivatives (carboxymethylcellulose sodium, polyvinylpyridone), crospovidone, cation exchange Resins and the like, and preferably, sodium starch glycolate having a property of rapidly absorbing water and swelling can be used.
- Glidants improve the fluidity during granule production, prevent adhesion of punches or rollers to the machine, and reduce resistance when withdrawing granules from the machine. It serves to facilitate layering in the formulation.
- talc hydrogenated castor oil
- magnesium stearate calcium stearate
- silicon dioxide stearic acid
- magnesium stearate or a mixture of idol
- microcrystalline cellulose lactose, glucose, mannirol, alginate, alkaline earth metal salt, clay, polyethylene glycol and dicalcium phosphate, and the like, and commonly used desiccant, sweetener or desiccant, etc. It may be included within a range that does not impair the effect, and the preferred type and content of the additives may be combined with those skilled in the art according to a technique known in the art. It may be appropriately selected and applied in consideration of the properties, dosages and formulation properties of the ingredients used.
- granulation of the main drug, temozolomide, together with the pH stabilizer as described above can improve the moisture content and the mixing uniformity as compared to the simple mixing and providing them as a mixture.
- tartaric acid which is a component used to adjust the pH
- temozolomide a component used to adjust the pH
- tartaric acid is added at a lower ratio than the main medicine, and in contrast to bulky (temozolomide), it is a colorless and transparent crystal form. It is difficult to ensure that the separation of the mixture does not occur in order to ensure uniform stability as a result.
- wet granulation and dry granulation can be applied.
- tartaric acid as a pH stabilizer
- crystalline tartaric acid is dissolved in water or an organic solvent and then wetted in a mixture to be used as a binder.
- a manufacturing method used in a general pharmaceutical process, or using such a method may reduce the stability of water-sensitive temozolomide or change physical properties due to organic solvents.
- the granules according to the preferred embodiment of the present invention may be dry granules, preferably assembled by dry granulation.
- dry granule is meant herein granules formed substantially without the use of externally applied granulation solvents such as water or ethanol.
- Wet granules refers to granules which have been granulated after drying the wet mass collected in solution at the preparation step using a solution as a binder using a convection ovone or fluid bed dryer to an appropriate temperature and time.
- the dry granulation method is a method of obtaining granules by roller compacting or slugging, and preferably roller compaction.
- the squeezer compaction refers to a method of preparing granules by squeezing at a constant pressure while passing the powder between two squeezers in detail. This allows the roller-compressed mixture to be further subjected to sizing or sieving using a fitz-mill or oscillator as needed to obtain granules of suitable size.
- Granules according to a preferred embodiment of the present invention described above may be provided in the form of a pharmaceutical composition, preferably further comprising a pharmaceutically acceptable additive.
- another preferred embodiment of the present invention provides a pharmaceutical composition with improved stability comprising the above-described granules and pharmaceutically acceptable additives.
- the pharmaceutically acceptable additives are added to the granules according to the preferred embodiment of the present invention as described above to constitute a pharmaceutical composition, and are distinguished from the additives included in the aforementioned granules. In the specification, for convenience, it is referred to as "post-mixing additive".
- the post-mixing additives may include, for example, excipients, stabilizers, lubricants, lubricants, buffers, sweeteners, base surfactants, adsorbents, copulating agents, binders, suspending agents, curing agents, antioxidants, binders, flavoring agents, flavoring agents, and pigments.
- Coating agents wetting agents, layering agents, defoamers, fresheners, chewing agents, antistatic agents, colorants, dispersants, disintegrants, waterproofing agents, preservatives, preservatives, dissolution aids, glidants, etc., each of the preferred examples described above The same may be applied as mentioned in the additives, but is not limited thereto, and conventional additives used in the art may be appropriately selected and used by those skilled in the art.
- the pharmaceutically acceptable additives may comprise a mixture of hydrophilic and hydrophobic lubricants.
- the hydrophilic lubricant may be at least one selected from the group consisting of stearic acid, sodium lauryl sulfate, and polyethylene glycol (for example, more than 4000 polyethylene glycol), the hydrophobic lubricant is magnesium stearate, talc, silicon dioxide and starch It may be one or more selected from the group consisting of.
- the mixture of hydrophilic and hydrophobic lubricants may preferably be a mixture of hydrophilic and hydrophobic lubricants in a weight ratio of 2: 1 to 1: 5.
- a glidant mixture mixed within the above range provides a temozolomide-containing formulation having improved physical properties, with improved flow properties and markedly superior stability while the dissolution pattern remains equivalent to that of the conventional formulation (Temodal®). can do.
- the hydrophilic lubricant and hydrophobic lubricant may be included in 0.05 to 3 parts by weight based on 100 parts by weight of the total pharmaceutical composition.
- the pharmaceutical composition may include temozolomide in a therapeutically effective amount, and the therapeutically effective amount means an amount suitable for the treatment or prevention of a disease, and the type of disease, the severity of the disease, and an active ingredient contained in the composition. And various factors including the type and content of other ingredients, the type of formulation and the age, weight, general state of health, sex and diet of the patient, time of administration, route of administration and rate of composition, duration of treatment, drugs used concurrently. Can be adjusted.
- the pharmaceutical composition of the present invention may be administered or administered in an effective amount of a total dose of 75 mg / m 2 to 200 mg / m 2 when administered or taken once to several times a day. have.
- the content of the active ingredient should be so high as not to cause side effects.
- temozolomide may be included in 3 to 60% by weight of the total pharmaceutical composition.
- the pharmaceutical composition may be preferably provided in the form of an oral preparation, and the oral preparation may preferably be a capsule, powder, granule, or tablet, but is not limited thereto.
- the temozolomide in the pharmaceutical composition and specific formulations thereof may be at least 90% by weight, or substantially all amounts present in the granules described above.
- Another preferred embodiment of the present invention provides a method for producing a granule and the pharmaceutical composition comprising the same.
- a method for preparing a pharmaceutical composition having improved stability may include the steps of: a) mixing temozolomide with tartaric acid as a pH stabilizer; b) forming and granulating dry granules with the mixture; And c) mixing the granulated particles with a pharmaceutically acceptable additive.
- Step a) may be to further mix a pharmaceutically acceptable additive, preferably including an anti-caking agent.
- the step a) is a pharmaceutically acceptable additive widely used in the art, that is, any one or more of excipients, binders, disintegrants, lubricants, and diluents and other commonly used desiccants, sweeteners, or humectants It may be to add by adding a shake.
- the mixture prepared through step a) may then be granulated through step b).
- the granulation formation in step b) ensures uniform stability as described above.
- it may be preferably by dry granulation method, and more preferably by using dry granulation method by squeezing. This allows the er-compressed mixture to be further subjected to sizing or sieving using a fitz-mill, oscillator or the like as necessary to obtain granules of suitable size.
- the granules established through step b) may then be further mixed with pharmaceutically acceptable additives through step c) to produce a pharmaceutical composition with improved stability.
- the pharmaceutically acceptable additive of step c) may be referred to as a compounding additive after convenience for convenience as described above, which may preferably include sugars, starches, polysaccharide cellulose derivatives, or ' mixtures thereof. However, without being limited thereto, additives widely used in the art may be appropriately selected and used by those skilled in the art.
- the pharmaceutically acceptable additive of step C) may be a mixture of hydrophilic and hydrophobic lubricants, wherein the hydrophilic and hydrophobic lubricants are mixed in a weight ratio of 2: 1 to 1: 5.
- hydrophilic excipients e.g. lactose, etc.
- pharmaceutically acceptable additives which may be used in step a) are preferably added in step c) rather than step a) and mixed with the granules prepared in step b).
- hydrophilic excipients e.g. lactose, etc.
- Formulated to improve stability and elute equivalent to conventional commercial products Formulations with a secured pattern can be prepared.
- pH stabilizer anti-caking agent
- pharmaceutically acceptable additives addition and post-mixing additives in granules
- dry granulation methods are described above with respect to granules and pharmaceutical compositions including the same according to the preferred embodiment of the present invention. Can be applied as is.
- the improved pharmaceutical composition prepared through the step C) may be provided in various formulations through a process such as layering in a capsule or tableting using a tableting machine.
- the oral preparations may preferably be, but are not limited to, capsules, powders, granules, or tablets.
- the oral preparations containing temozolomide prepared as described above can be used to treat and prevent other proliferative diseases as well as therapeutic agents for glioma glioblastoma multiforme glioblastoma, brain tumor of the ventricular stromal cell tumor because of maintaining the original activity of the active ingredient. It can be usefully used as an oral preparation with improved stability to the external environment such as water.
- the formulations according to the present invention have improved stability to pH and moisture, which not only ensure the stability of the main drug, temozolomide, after the process and packaging, but also can be stored for a long time, improve productivity by improving flowability, and oral It can be applied as a formulation to maintain excellent content uniformity and drug activity, which can be useful for the treatment of brain tumors.
- FIG. 2 compares the change of properties at 3 months after preparation of the dry granule formulation (Example 1), the wet granule formulation (Comparative Example 1) and the control agent (Comparative Example 3) according to Experimental Example 1.
- FIG. 2 compares the change of properties at 3 months after preparation of the dry granule formulation (Example 1), the wet granule formulation (Comparative Example 1) and the control agent (Comparative Example 3) according to Experimental Example 1.
- FIG. 2 compares the change of properties at 3 months after preparation of the dry granule formulation (Example 1), the wet granule formulation (Comparative Example 1) and the control agent (Comparative Example 3) according to Experimental Example 1.
- FIG. 2 compares the change of properties at 3 months after preparation of the dry granule formulation (Example 1), the wet granule formulation (Comparative Example 1) and the control agent (Comparative Example 3) according to Experimental Example 1.
- FIG. 2 compares the change of properties at 3 months after preparation
- Figure 3 shows the dissolution test results according to Experimental Example 2.
- Figure 4 shows the stability test results according to Experimental Example 3.
- Example 1 Comparative Examples as ingredients, contents and preparation methods as shown in Table 1 below.
- Comparative Example 3 a commercially available temodal 250 mg capsule (Schering Corporation) was used.
- the analog was analyzed by HPLC and the conditions are as follows.
- Mobile phase Mix 960 ml of 0.5% glacial acetic acid solution with 40 ml of methanol, dissolve 0.94 g / l (0.005 M) of sodium sulphonate in this solution and filter with 0.45 / m filter
- Comparative Example 2 prepared by a simple mixing process without granulation (A of FIG. 1), it was observed at one month after preparation, and granulation.
- Comparative Example 1 Compared with the formulation (B of FIG. 1), the layered product was not only discolored, but also showed uniformity in several places, and discoloration of the capsule was also observed, indicating that the simple mixed formulations had poor water stability compared to the granule formulations.
- Comparative Example 3 which is a reference drug
- Comparative Example 1 also changes in content and lead substance as much as 3.5% by weight after 1 month, and 5.3% by weight after 2 months.
- the formulation of Example 1 was found to adhere to about 2.9% by weight, which is about half of the reference drug, even after 2 months, and the amount of the flexible substance was measured.
- the formulation showed a rapid increase in the amount of flexible substances after 1 month, reaching 0.13% by weight, whereas the formulation of Example 1 showed 0.02% of the flexible substance after 2 months, compared to the reference drug of Comparative Example 3. / 8 was found to be only.
- Example 2 granulated formulation of Example was confirmed that the storage stability was remarkably improved as well as the simple mixed formulation of Comparative Example 2 as well as the inhibitory effect of the generation of the flexible substance than the reference drug of Comparative Example 3.
- the dry granules of Example 1 showed less change in properties, content, and softening substance than the wet granules of Comparative Example 1, and thus, it was confirmed that the dry granules had better physical properties.
- Comparative Example 2 which is a simple mixed formulation, it was confirmed that the stability in the short time as described above did not proceed any further experiment. Table 2
- the dissolution test was carried out with reference to the test method of the temozolomide formulation described in the US-FDA dissolution method.
- dry granules were prepared by varying the composition, content, and preparation method of the composition in order to secure better physical properties with respect to the dry granule formulation of Example 1 having improved stability.
- Lactose was added after dry granulation and formulation, mixed for 5 minutes, and again mixed with 5 minutes by adding 1.35 g of stearic acid, and prepared in the same manner as in Example 1, and 450 mg of this mixture was precisely taken. Stratified on
- Lactose was added after dry granulation and formulation, and mixed for 5 minutes, and again mixed with 5 minutes by adding 0.68 g of stearic acid and 0.57 g of magnesium stearate, and then prepared in the same manner as in Example 1, to obtain 449 mg of this mixture.
Landscapes
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2015550304A JP6051317B2 (ja) | 2012-12-31 | 2013-12-20 | テモゾロミドを含む安定性が改善された薬剤学的組成物およびその製造方法 |
US14/758,252 US20160199302A1 (en) | 2012-12-31 | 2013-12-20 | Pharmaceutical Composition Comprising Temozolomide With Improved Stability and Process for Manufacturing the Same |
EP13869093.8A EP2939662B1 (en) | 2012-12-31 | 2013-12-20 | Pharmaceutical composition comprising temozolomide with improved stability and process for manufacturing the same |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020120158569A KR20140087846A (ko) | 2012-12-31 | 2012-12-31 | 테모졸로미드를 포함하는 안정성이 개선된 약제학적 조성물 및 이의 제조방법 |
KR10-2012-0158569 | 2012-12-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2014104671A1 true WO2014104671A1 (ko) | 2014-07-03 |
Family
ID=51021652
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2013/011973 WO2014104671A1 (ko) | 2012-12-31 | 2013-12-20 | 테모졸로미드를 포함하는 안정성이 개선된 약제학적 조성물 및 이의 제조방법 |
Country Status (5)
Country | Link |
---|---|
US (1) | US20160199302A1 (ko) |
EP (1) | EP2939662B1 (ko) |
JP (1) | JP6051317B2 (ko) |
KR (1) | KR20140087846A (ko) |
WO (1) | WO2014104671A1 (ko) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10806732B2 (en) * | 2016-05-02 | 2020-10-20 | Double Bond Pharmaceutical AB | Stable anti-neoplastic pharmaceutical composition comprising temozolomide and method of preparing the composition |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20160117070A (ko) * | 2015-03-31 | 2016-10-10 | 한미약품 주식회사 | 오셀타미비어 함유 경구용 고형제제 및 그 제조방법 |
CA3062764A1 (en) * | 2016-04-28 | 2017-11-02 | Amplipharm Pharmaceuticals, LLC | Temozolomide powder formulation |
US9949967B2 (en) | 2016-04-28 | 2018-04-24 | Amplipharm Pharmaceuticals, LLC | Temozolomide powder formulation |
US10285987B2 (en) | 2017-04-28 | 2019-05-14 | Amplipharm Pharmaceuticals, LLC | Device and kit for dosing and dispensing non-liquid medicine |
WO2018004261A1 (ko) * | 2016-06-30 | 2018-01-04 | 한미약품 주식회사 | 오셀타미비어 함유 경구용 고형제제 및 그 제조방법 |
US11147810B2 (en) * | 2017-03-13 | 2021-10-19 | Ftf Pharma Private Limited | Pharmaceutical composition of oral suspension of anti-neoplastic alkylating agents |
WO2018200034A1 (en) * | 2017-04-28 | 2018-11-01 | Amplipharm Pharmaceuticals, LLC | Device and kit for dosing and dispensing non-liquid medicine |
WO2019014420A1 (en) * | 2017-07-12 | 2019-01-17 | Azhc, Llc | COMPOSITIONS AND METHODS FOR REDUCING MEDICATION ERRORS |
CN107397735B (zh) * | 2017-07-28 | 2020-07-10 | 东曜药业有限公司 | 一种替莫唑胺药物组合物及其制备方法和应用 |
WO2021009700A1 (en) * | 2019-07-16 | 2021-01-21 | Intas Pharmaceuticals Ltd. | Pharmaceutical composition of temozolomide. |
WO2022072099A1 (en) * | 2020-09-30 | 2022-04-07 | Eirgen Pharma, Ltd | Immediate release dosage forms, methods of making and using |
WO2023150569A1 (en) * | 2022-02-01 | 2023-08-10 | The Board Of Trustees Of The University Of Illinois | Imidazotetrazine compounds and treatment of tmz-resistant cancers |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5260291A (en) | 1981-08-24 | 1993-11-09 | Cancer Research Campaign Technology Limited | Tetrazine derivatives |
US5939098A (en) * | 1996-09-19 | 1999-08-17 | Schering Corporation | Cancer treatment with temozolomide |
US20070112053A1 (en) * | 2005-09-16 | 2007-05-17 | Pickett Cecil B | Pharmaceutical compositions and methods using temozolomide and a protein kinase inhibitor |
US20080044457A1 (en) * | 2004-09-22 | 2008-02-21 | Tian Jin Kinsly Pharmaceutical R&D Co. Ltd. | Pharmaceutical Composition Comprising Temozolomide Ester |
WO2011036676A2 (en) * | 2009-09-23 | 2011-03-31 | Ashwini Nangia | Stable cocrystals of temozolomide |
KR20120121944A (ko) * | 2011-04-27 | 2012-11-07 | 영진약품공업주식회사 | 안정성이 개선된 리마프로스트 함유 약제학적 조성물 및 이의 제조방법 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7294332B2 (en) * | 1995-10-04 | 2007-11-13 | Schering Corporation | Combination therapy (temozolomide and α-IFN) for advanced cancer |
CA2184545A1 (en) * | 1996-07-31 | 1998-02-01 | Pascale Reidenberg | Cancer treatment with temozolomide |
KR20040063975A (ko) * | 2001-11-30 | 2004-07-15 | 화이자 프로덕츠 인크. | 5,8,14-트리아자테트라시클로[10.3.1.0(2,11).0(4,9)]-헥사데카-2(11)3,5,7,9-펜타엔의 약학 조성물 |
KR20040091135A (ko) * | 2002-03-14 | 2004-10-27 | 다이이찌 산토리 파마 가부시키가이샤 | 염산 필지카이니드 함유 정제(건식) |
US20110142889A1 (en) * | 2009-12-16 | 2011-06-16 | Nod Pharmaceuticals, Inc. | Compositions and methods for oral drug delivery |
-
2012
- 2012-12-31 KR KR1020120158569A patent/KR20140087846A/ko active Application Filing
-
2013
- 2013-12-20 WO PCT/KR2013/011973 patent/WO2014104671A1/ko active Application Filing
- 2013-12-20 EP EP13869093.8A patent/EP2939662B1/en active Active
- 2013-12-20 US US14/758,252 patent/US20160199302A1/en not_active Abandoned
- 2013-12-20 JP JP2015550304A patent/JP6051317B2/ja active Active
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5260291A (en) | 1981-08-24 | 1993-11-09 | Cancer Research Campaign Technology Limited | Tetrazine derivatives |
US5939098A (en) * | 1996-09-19 | 1999-08-17 | Schering Corporation | Cancer treatment with temozolomide |
US20080044457A1 (en) * | 2004-09-22 | 2008-02-21 | Tian Jin Kinsly Pharmaceutical R&D Co. Ltd. | Pharmaceutical Composition Comprising Temozolomide Ester |
US20070112053A1 (en) * | 2005-09-16 | 2007-05-17 | Pickett Cecil B | Pharmaceutical compositions and methods using temozolomide and a protein kinase inhibitor |
WO2011036676A2 (en) * | 2009-09-23 | 2011-03-31 | Ashwini Nangia | Stable cocrystals of temozolomide |
KR20120121944A (ko) * | 2011-04-27 | 2012-11-07 | 영진약품공업주식회사 | 안정성이 개선된 리마프로스트 함유 약제학적 조성물 및 이의 제조방법 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10806732B2 (en) * | 2016-05-02 | 2020-10-20 | Double Bond Pharmaceutical AB | Stable anti-neoplastic pharmaceutical composition comprising temozolomide and method of preparing the composition |
Also Published As
Publication number | Publication date |
---|---|
EP2939662A4 (en) | 2016-06-15 |
JP2016504350A (ja) | 2016-02-12 |
EP2939662B1 (en) | 2019-10-02 |
KR20140087846A (ko) | 2014-07-09 |
US20160199302A1 (en) | 2016-07-14 |
JP6051317B2 (ja) | 2016-12-27 |
EP2939662A1 (en) | 2015-11-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2014104671A1 (ko) | 테모졸로미드를 포함하는 안정성이 개선된 약제학적 조성물 및 이의 제조방법 | |
EP2136793B1 (en) | Tablet formulations containing 8-[{1-(3,5-bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one salts and tablets made therefrom | |
EP2777696B1 (en) | Preparation of stable pharmaceutical dosage forms | |
KR101977785B1 (ko) | 에제티미브 및 로수바스타틴을 포함하는 경구용 복합제제 및 그 제조방법 | |
WO2020249001A1 (zh) | 一种含有布鲁顿氏酪氨酸激酶抑制剂的口服固体片剂及其制备方法 | |
TWI727935B (zh) | 含有細胞週期蛋白抑制劑固體分散體的醫藥組成物及其製備方法 | |
CN102764264A (zh) | 一种具高溶出度的塞来昔布固体组合物、制备方法及应用 | |
EP2934488B1 (en) | A pharmaceutical composition containing candesartan cilexetil and amlodipine | |
CN109875972B (zh) | 一种奥美沙坦酯氨氯地平药物组合物 | |
US11000523B2 (en) | Ceritinib formulation | |
CN102499923A (zh) | 一种药物组合物、其制备方法及用途 | |
CN103372014A (zh) | 一种能快速溶出、稳定的盐酸伐地那非口服固体制剂及其制备方法 | |
WO2006123213A1 (en) | Modified release formulations of gliclazide | |
CN103610658A (zh) | 一种免疫调节剂缓释剂及其制备方法 | |
EP2538924B1 (en) | Solid pharmaceutical formulations of ramipril and amlodipine besylate, and their preparation | |
RU2613192C1 (ru) | Таблетки клозапина с пролонгированным высвобождением | |
NZ760233A (en) | Compositions and methods for treatment of abnormal cell growth | |
CN103505466B (zh) | 含有盐酸二甲双胍与格列美脲的固体复方制剂及其制备方法和用途 | |
KR101794573B1 (ko) | 콜린알포세레이트를 포함하는 속방출형 고형제제 및 이의 제조방법 | |
EP2915526A1 (en) | Pharmaceutical compositions comprising anagrelide | |
CN102058602B (zh) | 一种稳定的含氯沙坦钾和氢***的口服固体制剂 | |
WO2007049626A1 (ja) | カベルゴリン含有経口固形製剤 | |
KR101737058B1 (ko) | 테모졸로미드를 포함하는 안정성이 개선된 약제학적 조성물 및 이의 제조방법 | |
CN112057427A (zh) | 一种含有布鲁顿氏酪氨酸激酶抑制剂的口服固体片剂及其制备方法 | |
KR20150096787A (ko) | N-[5-[2-(3,5-디메톡시페닐)에틸]-2h-피라졸-3-일]-4-[(3r,5s)-3,5-디메틸피페라진-1-일]벤즈아미드의 약학 제제 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 13869093 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2015550304 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14758252 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2013869093 Country of ref document: EP |